申请人:BANYU PHARMACEUTICAL CO., LTD.
公开号:EP2072519A1
公开(公告)日:2009-06-24
Provided is a compound of a formula (I):
[wherein R1a and R1b are the same or different, representing a hydrogen atom, etc.; R2a and R2b are the same or different, representing a hydrogen atom, etc., or R2a and R2b, taken together, form -CH2CH2-, R3a and R3b are the same or different, representing a hydrogen atom, etc.; or R3a and R3b, taken together, form - CH2CH2-etc.; Y1 and Y2 represent -C(R)2-, etc.; Z represents OR, NR2, etc.; R represents a hydrogen atom, a C1-6 alkyl group, etc.; Ar1 represents a 6-membered aromatic carbocyclic group, etc.; Ar2 represents a 6-membered aromatic carbocyclic group, etc; A3 represents a 6-membered aromatic carbocyclic group etc.]. The compound is useful as a medicine for central disorders, cardiovascular disorders, metabolic disorders.
本文提供了一种式 (I) 的化合物:
[其中 R1a 和 R1b 相同或不同,代表氢原子等;R2a 和 R2b 相同或不同,代表氢原子等、或 R2a 和 R2b 相同或不同,代表氢原子等;或 R3a 和 R3b 相同或不同,代表-CH2CH2-等; Y1 和 Y2 代表-C(R)2-等; Z 代表 OR、NR2 等。R 代表氢原子、C1-6 烷基等;Ar1 代表 6 元芳香碳环基团等;Ar2 代表 6 元芳香碳环基团等;A3 代表 6 元芳香碳环基团等]。该化合物可作为治疗中枢性疾病、心血管疾病和代谢紊乱的药物。